Patient Centricity in Clinical Trials: Solutions for the Evolving Landscape

Life Sciences, Clinical Trials, Pharmaceutical, Patient Recruitment & Retention, Pharma Manufacturing & Supply Chain,
  • Tuesday, March 29, 2022

Two years into the pandemic, it’s clear that decentralized clinical trials are here to stay. Approximately 70 percent of patients live more than 2 hours from clinical trial sites. Therefore, decentralized or hybrid studies can improve patient centricity in clinical trials by reducing patient burden and improving patient retention.

Join decentralized clinical trial experts in this complimentary webinar to explore industry trends, operational obstacles and the evolving patient journey. The featured speakers will examine components of a patient-focused, flexible supply chain strategy. In addition, there will be a discussion about how sponsors and investigator sites can benefit from pandemic-era lessons learned.

In this webinar, attendees will learn about:


Industry Trends:

  • Clinical trials now and post-pandemic are expected to contain many decentralized trial elements
  • The current operational obstacles seen in decentralized studies
  • Critical need for flexibility and collaboration amongst all stakeholders

Patient Centricity in Clinical Trials with Decentralized Studies:

  • Many challenges with traditional ways of doing studies
  • How a patient-centric study design offers numerous advantages: easier and faster recruitment, better retention and greater diversity
  • Combining direct to patient logistics, Home Health Care and technology for greater impact

Components of a Patient-Centric Approach to Decentralized Clinical Trials:

  • Agile supply chain strategy
  • Home Health Care
  • Technology

Key Takeaways:

    • Impact of COVID-19 on clinical trial study design — decentralized clinical trials are here to stay
    • Studies that focus on the patient experience offer significant advantages to sponsors
    • Technology, data integration and an agile supply chain strategy together are key for success

Read Less...


Robin Douglas, Marken

Robin Douglas, Senior Director Global Patient Centric Services, Marken

Robin Douglas has a career in clinical research that spans over 28 years and includes experience in strategy, innovation, clinical operations, decentralized clinical trial implementation and technology solutions. As Senior Director of Global Patient Centric Services (GPCS) at Marken, she is responsible for home health care services in North and Latin America and currently oversees home health care operations, technology and quality control.

Message Presenter

Gaurang Majmudar, Senior Director Patient Centric Services, Marken

As Senior Director, Global Patient Centric Services at Marken, Gaurang is responsible for overseeing the expansion of Patient Centric Services in the Europe, Middle East and Africa (EMEA) and Asia Pacific (APAC) regions, and the development of new service offerings for clients to further expand and streamline the clinical trial experience for patients and sponsors.

Gaurang offers a wealth of experience from the pharmaceutical, distribution and home healthcare industries. He has held Senior Marketing and Commercial roles within pharmaceutical companies, where he was responsible for product development and launches within specialty medicines and orphan diseases sectors.

Message Presenter

Who Should Attend?

Senior professionals who are involved with:

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Central Labs
  • Contract Manufacturing Organizations (CMOs)
  • Contract Research Organizations (CROs)
  • Contract Development and Manufacturing Organizations (CDMOs)

What You Will Learn

  • The current industry trends and the components of a patient-centric approach to decentralized clinical trials
  • How a patient-centric study design offers numerous advantages, such as easier and faster recruitment, better retention and greater diversity
  • Technology, data integration and an agile supply chain strategy together are key for success

Xtalks Partner


Marken is a wholly owned subsidiary of UPS and is a critical part of UPS Healthcare. With Polar Speed and Marken included, the UPS Healthcare division staffs 128 locations with 5,500 employees worldwide. Marken offers a state-of-the-art GMP-compliant depot network and logistic hubs for clinical drug product storage and distribution in 58 locations worldwide, while maintaining the leading position for Direct-to-Patient and Home Healthcare services, biological sample shipments and biological kit production. Marken’s dedicated 1,900 staff members manage 120,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries. Additional services such as ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account